Clinical Trial: Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Ranibizumab in Idiopathic Macular Telangiectasia, Type 2. A Prospective Interventional Non-randomized Study Comparing the Efficacy and Safety of Intravitreal Ranibizumab i

Brief Summary: The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT). 10 patients will receive monthly injections of the drug into one eye over a period of one year.